KCT0000426
Recruiting
未知
Discovery and validation of genetic markers to establish effective indications of anti-osteoporotic drugs
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diseases of the musculo-skeletal system and connective tissue
- Sponsor
- Asan Medical Center
- Enrollment
- 6604
- Status
- Recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who visit Asan Medical Center for osteoporosis and give the informed consent.
- •Patients with measurement of bone mineral density (BMD) for osteoporosis (Classification of case / control group by BMD result)
- •Wahout peroid: Two years using agents more than 6 months against osteoporosis
Exclusion Criteria
- •1\. Subjects within wash\-out period
- •2\. Secondary osteoporosis: Disorders strongly associated with osteoporosis. These include rheumatoid arthritis, untreated long\-standing hyperthyroidism or Graves' disease, chronic liver disease, hyperparathyroidism, and parathyroid adenoma
- •3\. Other conditions were not suitable in cohort study: Chronic renal failure, active malignany, and transplantation
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Genetic study to identify genetic variants which affect clinical severity in Thai patients with beta thalassemia hemoglobin Eclinical variation in patients with beta thalassemia Hb E diseasebeta thalassemia Hb E disease, Thailand, genetic modifierTCTR20211022001Siriraj Hospital338
Not yet recruiting
Not Applicable
Biomarker signature discovery study to determine acute bacterial respiratory tract infection.NL-OMON56538evels Diagnostics300
Active, not recruiting
Phase 1
Biomarkers of Response to Pembrolizumab Combined with Chemotherapy in Non-Small Cell Lung Cancer (Keynote-782)EUCTR2018-002598-22-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
Active, not recruiting
Phase 1
Biomarkers of Response to Pembrolizumab Combined with Chemotherapy in Non-Small Cell Lung Cancer (Keynote-782)EUCTR2018-002598-22-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
Recruiting
Not Applicable
Development of molecular diagnostic markers using oral fluid for diagnosis of periodontitis in diabetesDiseases of the musculo-skeletal system and connective tissueKCT0001023Asan Medical Center24